- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05270265
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
February 9, 2023 updated by: University of Oxford
A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Vivax Malaria Vaccine Candidate Pvs25-IMX313 in Matrix-M1 Adjuvant in Healthy Adults Living in the UK
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Volunteers will be recruited into one of three groups (n=8-10 per group) at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford over approximately 18 months.
All volunteers will receive three doses of Pvs25-IMX313 in Matrix-M1, administered intramuscularly and given four weeks apart.
Enrolment will be staggered with clinical and safety reviews, follow-up visits and monitoring via a diary card.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LE
- CCVTM, University of Oxford, Churchill Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult aged 18 to 45 years.
- Able and willing (in the Investigator's opinion) to comply with all study requirements.
- Willing to allow the Investigators to discuss the volunteer's medical history with their GP.
- Volunteers with the potential to become pregnant only: must practice continuous effective contraception for the duration of the study. Acceptable forms of contraception for volunteers of child-bearing potential are: Established use of oral, injected or implanted hormonal methods of contraception, Placement of an intrauterine device or intrauterine system, Male sterilization (if the vasectomised partner is the sole partner for the participant), True abstinence from sex with sperm-producing partners, when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence and withdrawal are not acceptable methods of contraception).
- Agreement to refrain from blood donation for the duration of the study.
- Able and willing to provide written informed consent to participate in the trial.
Exclusion Criteria:
- History of clinical malaria (any species).
- Travel to a clearly malaria endemic locality during the study period or within the preceding six months.
- Use of immunoglobulins or blood products (e.g., blood transfusion) in the last three months.
- Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days following each study vaccination, with the exception of --COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination.
- Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
- Concurrent involvement in another clinical trial or planned involvement during the study period.
- Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator.
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
- History of allergic disease or reactions likely to be exacerbated by any component of the -vaccine.
- Any history of anaphylaxis in reaction to vaccinations.
- Pregnancy, lactation or intention to become pregnant during the study.
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- History of serious psychiatric condition that may affect participation in the study.
- Any other serious chronic illness requiring hospital specialist supervision.
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week.
- Suspected or known injecting drug abuse in the 5 years preceding enrolment.
- Hepatitis B surface antigen (HBsAg) detected in serum.
- Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless volunteer has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV ribonucleic acid (RNA) PCR at screening for this study).
- Volunteers unable to be closely followed for social, geographic or psychological reasons.
- Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in SOP VC027.
- Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
- Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate.
Vaccination and re-vaccination exclusion criteria:
Absolute CI's:
- Anaphylactic reaction following administration of vaccine
- Pregnancy
CI's at that point in time (may be rescheduled):
- Acute disease (moderate/severe illness with or without fever)
- T>37.5C
- Current COVID-19 infection, defined as ongoing symptoms with positive COVID-19 PCR swab test taken during current illness or positive COVID-19 PCR swab test within preceding 14 days without symptoms. Vaccinations will be delayed by a minimum of 2 weeks from the date of the first positive COVID-19 PCR swab, as long as symptoms are improving or resolved. It will be at the discretion of the Investigator to withdraw a participant if they develop severe COVID-19 disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group 1 (low dose)
8-10 volunteers receiving three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
|
EXPERIMENTAL: Group 2 (standard dose)
8-10 volunteers receiving three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
|
EXPERIMENTAL: Group 3 (fractional dose)
8-10 volunteers receiving two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess safety and tolerability of the Pvs25-IMX313/Matrix-M1 vaccine in healthy adult volunteers by assessing occurrence of solicited local reactogenicity signs and symptoms in the 7 days following each vaccination using the patient-reported e-diaries
Time Frame: 7 days following each vaccination
|
Occurrence of solicited local reactogenicity signs and symptoms using the patient-reported e-diaries
|
7 days following each vaccination
|
To assess safety and tolerability of the Pvs25-IMX313/Matrix-M1 vaccine in healthy adult volunteers by assessing occurrence of solicited systemic reactogenicity signs and symptoms in the 7 days following each vaccination using patient-reported e-diaries
Time Frame: 7 days following each vaccination
|
Occurrence of solicited systemic reactogenicity signs and symptoms using the patient-reported e-diaries
|
7 days following each vaccination
|
Safety and tolerability of the Pvs25-IMX313/Matrix-M1 vaccine in healthy adult volunteers, assessed through collection of data on the frequency, duration and severity of solicited and unsolicited adverse events.
Time Frame: 28 days following the vaccination
|
The specific endpoints for safety and tolerability will be actively and passively collected data on adverse event
|
28 days following the vaccination
|
Safety of the Pvs25-IMX313/Matrix-M1 vaccine in healthy adult volunteers, assessed through the number of participants with abnormal laboratory test results
Time Frame: 28 days following vaccination
|
Occurrence of change from baseline laboratory test results
|
28 days following vaccination
|
Assessment of the safety and tolerability of the Pvs25-IMx313/Matrix-M1 vaccine in healthy adult volunteers assessed through the number of participants with serious adverse events
Time Frame: Whole duration of the study period (8 months following enrolment)
|
Occurrence of serious adverse events including grading of causality
|
Whole duration of the study period (8 months following enrolment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the humoral immunogenicity of the Pvs25-IMX313/Matric-M1 vaccine, when administered to healthy adult volunteers as assessed by humoral responses to the Pvs25 protein
Time Frame: Days 1, 29, 57, 140 and 240.
|
Antibody responses to the Pvs25 protein will be assessed through total IgG isotypes and avidity
|
Days 1, 29, 57, 140 and 240.
|
Assessment of the cellular immunogenicity of the Pvs25-IMX313/Matrix-M1 vaccine, when administered to healthy adult volunteers as assessed by cellular responses to the Pvs25 protein.
Time Frame: Days 1, 29, 57, 140 and 240.
|
T cell responses to Pvs25 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot) and flow cytometry assays.
|
Days 1, 29, 57, 140 and 240.
|
Assessment of ex vivo efficacy of the Pvs25-IMX313/Matrix-M1 vaccine when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-reducing activity.
Time Frame: Days 1, 29, 57, 140 and 240.
|
Transmission-reducing activity
|
Days 1, 29, 57, 140 and 240.
|
Assessment of ex vivo efficacy of the Pvs25-IMX313/Matrix-M1 vaccine when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-blocking activity.
Time Frame: Days 1, 29, 57, 140 and 240.
|
Transmission-blocking activity
|
Days 1, 29, 57, 140 and 240.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 9, 2022
Primary Completion (ANTICIPATED)
September 30, 2023
Study Completion (ANTICIPATED)
September 30, 2023
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
March 7, 2022
First Posted (ACTUAL)
March 8, 2022
Study Record Updates
Last Update Posted (ACTUAL)
February 13, 2023
Last Update Submitted That Met QC Criteria
February 9, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC084
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria, Vivax
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
Centers for Disease Control and PreventionTerminated
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
-
Menzies School of Health ResearchUniversity of Melbourne; Curtin University; Addis Ababa University; Fundação de... and other collaboratorsNot yet recruitingVivax MalariaBrazil, Ethiopia, Indonesia, Papua New Guinea
-
University of OxfordCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompletedMalaria | Vivax MalariaPakistan
Clinical Trials on Pvs25-IMX313/Matrix-M1
-
University of OxfordTerminatedMalaria,FalciparumUnited Kingdom
-
University of OxfordIfakara Health InstituteRecruiting
-
European Vaccine InitiativeUniversity of Oxford; Malaria Research and Training Center, Bamako, MaliNot yet recruitingHealthy Women of Child Bearing Potential
-
University of OxfordRecruitingMalaria, VivaxUnited Kingdom
-
University of OxfordCompleted
-
University of OxfordCompleted
-
NovavaxDepartment of Health and Human ServicesCompletedCovid19 | SARS-CoV InfectionUnited States, Mexico, Puerto Rico
-
NovavaxDepartment of Health and Human ServicesCompleted
-
NovavaxActive, not recruitingCOVID-19Spain, United States, South Africa, Mexico, United Kingdom, Philippines, Colombia, Dominican Republic, Guatemala, Honduras
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingEBV | Epstein-Barr Virus Infection | Infectious MononucleosisUnited States